About us
Future COPD is a non-periodical medical publication. The journal publishes meeting reports of medical events on demand. The articles are not indexed and they are not peer reviewed. All reports are developed by professional medical writers. The authors revise and approve the reports. The sponsor of the meeting has exclusive distribution rights for those reports.
Future COPD is a trade mark from Content Ed Net Communications SL, Spain.
Disclaimer:
While every effort has been made to ensure that the contents of this publication are factually correct, neither the authors nor the publisher accepts, and they hereby expressly exclude to the fullest extent permissible under applicable law, any and all claims arising from the contents published in this material, including, without limitation, or for any errors, omissions, inaccuracies in original or following translation, or for any consequences arising therefrom. Nothing in this notice shall exclude liability that may not be excluded by law. Approved product information should be reviewed before prescribing. All rights reserved. No part of this publication may be reproduced, stored in an electronic retrieval system or transmitted in any copied form or by any other means, electronic, mechanical by photocopying, recording or otherwise, without the prior written permission of Content Ed Net Communications, S.L.
Summary reports 2017 - 2020:
-
Paving the way to personalized medicine in chronic obstructive pulmonary disease and alpha-1-antitrypsin deficiency
European Respiratory Society Annual International Congress
2017, Milan, ItalyJoanna Chorostowska-Wynimko, Timm Greulich, José Luis López-Campos
Alpha-1-antitrypsin deficiency (AATD) is a rare, but important, genetic cause of chronic obstructive pulmonary disease (COPD). Approximately 120,000 people in Europe have the homozygous Pi*ZZ mutation. It is important to identify patients with AATD because they are at increased risk of hospitalization, they may benefit from augmentation therapy, and because, if detected early enough, they can benefit from smoking prevention strategies.
-
Advances in Genetic COPD: Implementation of AATD Research Findings in Clinical Practice
European Respiratory Society Annual International Congress
2018, Paris, FranceRobert Stockley, Sabina Janciauskiene, Adolfo Baloira, Noel Gerard McElvaney
The diagnostic and therapeutic importance of genetics in modern day medicine cannot be underestimated, and respiratory medicine is no exception. Increasing numbers of genetic variants associated with chronic obstructive pulmonary disease (COPD) have been identified, yet α1-antitrypsin (AAT) encoded by the SERPINA1 gene, is the only well recognized genetic variant associated with COPD.
-
The challenge and opportunity of managing AATD, bronchiectasis and COPD: You can make a difference
European Respiratory Society Annual International Congress
2019, Madrid, SpainMarc Miravitlles, Timm Greulich, Francesco Blasi, Michael R Loebinger
Alpha 1-antitrypsin deficiency (AATD) is an under-diagnosed condition. Many patients with chronic obstructive pulmonary disease (COPD) have never been tested for AATD, and a proportion of patients with bronchiectasis may unknowingly suffer from this genetic condition. To improve patient outcomes, it is essential that we increase the awareness of AATD amongst our colleagues so that, collectively, we can provide better diagnosis and treatment.
-
“Mind the gap”: evidence on the treatment of alpha-1 antitrypsin deficiency and unmet needs
European Respiratory Society Annual Meeting Congress
2020, Virtual meetingClaus F Vogelmeier, Robert A Sandhaus, Marc Miravitlles, Oliver J McElvaney
Alpha-1 antitrypsin deficiency (AATD) is a common but under-recognized genetic condition that affects approximately 1 in 2000 to 1 in 5000 individuals and predisposes to early-onset emphysema and liver disease. Although great improvements have been made in understanding the pathophysiology of AATD in recent years, many questions remain unanswered and the disease continues to pose several important challenges.